LR Jaidev*, Laxmi S. Chede and Hemanth K. Kandikattu Pages 203 - 214 ( 12 )
Pancreatic cancer is one of the low vascular permeable tumors with a high mortality rate. The five-year survival period is ~5%. The field of drug delivery is at its pace in developing unique drug delivery carriers to treat high mortality rate cancers such as pancreatic cancer. Theranostic nanoparticles are the new novel delivery carriers where the carrier is loaded with both diagnostic and therapeutic agents. The present review discusses various therapeutic and theranostic nanocarriers for pancreatic cancer.
Theranostics, pancreatic cancer, nanoparticles, chemotherapy, imaging, magnetic hyperthermia, combinatorial treatment and 3D pancreatic cancer.
College of Pharmacy, University of Iowa, 52246, Iowa, College of Pharmacy, University of Iowa, 52246, Iowa, Department of Medicine, Tulane Eosinophilic Disorders Centre (TEDC), Section of Pulmonary Diseases, Tulane University School of Medicine, New Orleans, LA 70112